CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 20-049/S006

ADMINISTRATIVE DOCUMENTS

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION

APPLICATION TO MARKET A NEW DRUG, BIOLOGIC, OR AN ANTIBIOTIC DRUG FOR HUMAN USE

(Title 21, Code of Federal Regulations, 314 & 601) =

Form Approved: OMB No. 0910-0338 Expiration Date: April 30, 2000 See OMB Statement on page 2.

FOR FDA USE ONLY

APPLICATION NUMBER

APPLICANT INFORMATION		•		<u> </u>					
NAME OF APPLICANT				DATE OF SUBMISSION					
Roberts Laboratories Inc.		August 6, 1999							
TELEPHONE NO. (Include Area Code)			FACSIMILE (FAX) Number (Include Area Code) (732) 676-1300						
			JTHORIZED U.S. AGENT NAME & ADDRESS (Number, Street, City, State, P Code, telephone & FAX number) IF APPLICABLE						
4 Industrial Way West Eatontown, NJ 07724-2274									
PRODUCT DESCRIPTION		I							
NEW DRUG OR ANTIBIOTIC APPLICATION NUMBER, OR BIOLOGICS LICENSE APPLICATION NUMBER (If previously issued) NDA 20-049									
ESTABLISHED NAME (e.g., Proper name, USP/USAN name) Mesalamine	PRIETARY N	NAME (trade name) IF ANY PENTASA®							
CHEMICAL/BIOCHEMICAL/BLOOD PRODUCT NAME (If any) 5-aminosalicylic acid									
OOSAGE FORM: STRENGTHS: 250			-	ROUTE OF ADMINISTRAT	ion: Dral				
(PROPOSED) INDICATION(S) FOR USE: Treatment of ulcerative colitis									
APPLICATION INFORMATION									
APPLICATION TYPE (check one)									
☐ BIOLOGICS LICENSE APPLICATION (21 CFR part 601)									
IF AN NDA, IDENTIFY THE APPROPRIATE TYPE So	5 (b) (1)	□ 505 (I	b) (2)	□ 507					
IF AN ANDA, OR AADA, IDENTIFY THE REFERENCE LISTED DRUG PRODUCT THAT IS THE BASIS FOR THE SUBMISSION Name of Drug Holder of Approved Application									
TYPE OF SUBMISSION (check one) ORIGINAL APPLICATION SAME	NDMENT TO A PI	ENDING APPLIC	CATION	RESU	JBMISSION				
PRESUBMISSION ANNUAL REPORT STABLISHMENT DESCRIPTION SUPPLEMENT SUPAC SUPPLEMENT									
☐ EFFICACY SUPPLEMENT ☐ LABELING SUPPLEMENT ☐ CHEMISTRY MANUFACTURING AND CONTROLS SUPPLEMENT ☐ OTHER									
REASON FOR SUBMISSION FPL for Approvable Supplement NDA 20-049/S-006									
PROPOSED MARKETING STATUS (check one)	CRIPTION PRODU	JCT (Rx)		OVER THE COUNTER PRODUC	т (отс)				
NUMBER OF VOLUMES SUBMITTED TI	HIS APPLICATION	IIS X P	APER	☐ PAPER AND ELECTRONIC	☐ ELECTRONIC				
ESTABLISHMENT INFORMATION		•			····				
Provide locations of all manufacturing, packaging and control sites for drug substance and drug product (continuation sheets may be used if necessary). Include name, address, contact, telephone number, registration number (CFN), DMF number, and manufacturing steps and/or type of testing (e.g. Final dosage form, Stability testing) conducted at the site. Please indicate whether the site is ready for inspection or, if not, when it will be ready.									
Refer to approved NDA 20-049									
Cross References (list related License Applications, INDs, NDAs, PMAs, 510(k)s, IDEs, BMFs and DMFs referenced in the current Application)									
1									

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION

APPLICATION TO MARKET A NEW DRUG, BIOLOGIC, OR AN ANTIBIOTIC DRUG FOR HUMAN USE

(Title 21, Code of Federal Regulations, 314 & 601)

Form Approved: OMB No. 0910-0338 Expiration Date: April 30, 2000 See OMB Statement on page 2.

		-					FOR FDA USE ONLY		
							ON NUMBER		
APPLICANT INFORMATION						•			
NAME OF APPLICANT					DATE OF SUBMISSION				
Roberts Laboratories Inc.					November 20, 1998				
TELEPHONE NO. (Include Area Code) (732) 676-1200				FACSIMILE (FAX) Number (Include Area Code) (732) 676-1300					
					RIZED U.S. AGENT NAME & ADDRESS (Number, Street, City, State,				
U.S. License number if previously issued): ZIP Co				ode, telephone & FAX number) IF APPLICABLE					
4 Industrial Way West Eatontown, NJ 07724-2274									
PRODUCT DESCRIPTION									
ESTABLISHED NAME (e.g., Proper name, USP/USAN name) Mesalamine PROPRIETARY N					PENTASA				
CHEMICAL/BIOCHEMICAL/BLOOD PRODUCT NAME (If any) 5-aminosalicyclic acid					С	ODE NAME (If	any)		
DOSAGE FORM: STRENG Capsules			0 mg		ROUTE OF ADMINISTRATION:				
				Oral					
(PROPOSED) INDICATION(S) FOR USE:									
Treatment of ulcerative colitis.									
APPLICATION INFORMATION									
APPLICATION TYPE (check one) NEW DRUG APPLICATION (21 CFR 314.50) ABBREVIATED APPLICATION (ANDA, AADA, 21 CFR 314.94)									
☐ BIOLOGICS LICENSE APPLICATION (21 CFR part 601)									
IF AN NDA, IDENTIFY THE APPROPRIATE TYPE 🗵 505 (b) (1)	1	505 (b)	(2)		507			
IF AN ANDA, OR AADA, IDENTIFY THE REFERENCE LISTED DRUG PRODUCT THAT IS THE BASIS FOR THE SUBMISSION Name of Drug Holder of Approved Application									
TYPE OF SUBMISSION			•						
(check one) U ORIGINAL APPLICATION	☐ AMEND	MENT TO A	PENDING	APPLIÇAT	ION	RES	SUBMISSION		
PRESUBMISSION ANNUAL REPORT	□ ES	TABLISHM	ENT DESC	RIPTION S	SUPPLEMENT	•	SUPAC SUPPLEMENT		
☐ EFFICACY SUPPLEMENT									
REASON FOR SUBMISSION: Response To FDA Request For Information.									
PROPOSED MARKETING STATUS (check one)	CRIPTION PE	RODUCT (R	x)		OVER TH	E COUNTER PRO	DDUCT (OTC)		
NUMBER OF VOLUMES SUBMITTED	THIS APPL	ICATION IS	S X PAP	ER	PAPER A	ND ELECTRONIC	ELECTRONIC		
ESTABLISHMENT INFORMATION									
Provide locations of all manufacturing, packaging and control sites for drug substance and drug product (continuation sheets may be used if necessary). Include name, address, contact, telephone number, registration number (CFN), DMF number, and manufacturing steps and/or type of testing (e.g. Final dosage form, Stability testing) conducted at the site. Please indicate whether the site is ready for inspection or, if not, when it will be ready.									
Cross References (list related License Applications, INDs, NDAs, PMAs, 510(k)s, IDEs, BMFs and DMFs referenced in the current application)									
			•						